Table 3.
Treatment timeline of 20 patients with rGBM.
| Patient number | Time point of surgery | Time point of CCRT starting | Time point of CCRT ending | Time point of recurrence | Time point of treatment of anlotinib+TMZ | Time point of progress | Time point of death | Follow-up time |
|---|---|---|---|---|---|---|---|---|
| 1 | -4.3 | -3.6 | -2.1 | -1.1 | 0 | 5 | – | 18.2 |
| 2 | -8.3 | -7.3 | -5.8 | 0 | 0 | 6.1 | 11.9 | 11.9 |
| 3 | -5.7 | -4.7 | -3.2 | -1.7 | 0 | 5.8 | 7.6 | 7.6 |
| 4 | -7.2 | -6.2 | -4.7 | 0 | 0 | – | – | 17.3 |
| 5 | -6.8 | -5.3 | -3.8 | -1.1 | 0 | – | – | 16.8 |
| 6 | -5.2 | -4.5 | -3 | 0 | 0 | 5 | 8 | 8 |
| 7 | -10.7 | -9.9 | -8.3 | -1.3 | 0 | 2.3 | 4.2 | 4.2 |
| 8 | -7.9 | -6.1 | -4.6 | -0.1 | 0 | 4.5 | 5 | 5 |
| 9 | -8.9 | -7.6 | -6.1 | 0 | 0 | 5.1 | 7.3 | 7.3 |
| 10 | -6.5 | -5.3 | -3.8 | -0.7 | 0 | 2.2 | – | 13.4 |
| 11 | -6.4 | -4.8 | -3.3 | 0 | 0 | 6.4 | 9.8 | 9.8 |
| 12 | -19.1 | -16.8 | -15.3 | 0 | 0 | – | – | 13.9 |
| 13 | -23.1 | -21.4 | -19.8 | -0.2 | 0 | – | – | 11.5 |
| 14 | -11.6 | -10.5 | -9 | -0.5 | 0 | 9.6 | – | 11.3 |
| 15 | -11 | -9.7 | -8.2 | 0 | 0 | – | – | 11 |
| 16 | -4.4 | -3.1 | -1.6 | -0.1 | 0 | 4 | 8 | 8 |
| 17 | -5.6 | -4.4 | -2.9 | -2.1 | 0 | 8.8 | – | 11.6 |
| 18 | -6.1 | -5.3 | -3.8 | 0 | 0 | – | – | 7.6 |
| 19 | -6.3 | -5.4 | -3.9 | -0.3 | 0 | 2 | 2.8 | 2.8 |
| 20 | -9.2 | -8.0 | -6.4 | 0 | 0 | – | – | 6.3 |
| median | -6.8 | -5.4 | -3.9 | -0.1 | 0 | 6.1 | 11.9 | 13.4 |
Take ‘Time point of treatment of anlotinib+TMZ’ as the starting point of the timeline, denoted by 0, and the rest of the column is the interval time (months) of distance 0. -means no progress and no death.
Timepoint of surgery: The interval time point between the treatment of anlotinib combined with temozolomide (anlotinib+TMZ) and the first surgery.
Timepoint of CCRT starting: The interval time point between the treatment of anlotinib+TMZ and the start of concurrent chemoradiotherapy (CCRT).
Time point of CCRT ending: The interval time point between the treatment of anlotinib+TMZ and the end of CCRT.
Timepoint of recurrence: The interval time point between the treatment of anlotinib+TMZ and the disease recurrence.
Timepoint of treatment of anlotinib+TMZ: The time point at which the patients began to be treated with anlotinib+TMZ. We define it as 0.
Timepoint of progress: The interval time point between the disease progression and the treatment of anlotinib+TMZ.
Timepoint of death: The interval time point between the death and the use of anlotinib+TMZ.
Follow-up time: The time from the beginning of the treatment of anlotinib+TMZ to the present or death.